Case Report | Open Access
Yolaine Joueidi, Aline Rousselin, Céline Rozel, Philippe Loget, Dominique Ranchere Vince, Sylvie Odent, Franck Bourdeaut, Vincent Lavoue, Maela Le Lous, "Ultrasound Presentation of a Disseminated Fetal and Neonatal Rhabdoid Tumor", Case Reports in Obstetrics and Gynecology, vol. 2018, Article ID 6073204, 7 pages, 2018. https://doi.org/10.1155/2018/6073204
Ultrasound Presentation of a Disseminated Fetal and Neonatal Rhabdoid Tumor
This is a case report of a disseminated fetal rhabdoid tumor discovered at 32 weeks of gestation in a 29-year-old woman on immunosuppressive therapy. The mother consulted for a decrease in fetal movement. Fetal ultrasound showed signs of a disseminated tumor affecting the left armpit, liver, spleen, and limbs. A caesarian section was performed because of signs of fetal distress. Immunohistochemical analysis of a fetal biopsy showed deletion of the SMARCB1 gene. Pathological analysis of the placenta showed a rhabdoid tumor invading both fetal and maternal compartments. The mother underwent a whole-body MRI, and no metastasis was found. To the best of our knowledge, this is the first report of a disseminated rhabdoid tumor invading both fetal and maternal compartments.
1. Case Report
A 29-year-old pregnant woman who was being treated with azathioprine for autoimmune hepatitis consulted at 32 weeks of gestation for decreased fetal movement. Obstetric ultrasound revealed many heterogeneous, hypervascular fetal tumors in the left armpit (Figure 1), intra-abdominal organs, and subcutaneous space (Figure 2). There was no sign of fetal cardiac insufficiency or anemia (no pericardial effusion and the middle cerebral artery peak systolic velocity was 50 cm/sec or 1,07 MoM).
Fetal wellbeing was monitored daily and fetal lung maturity was induced at 32 weeks of gestation and 2 days with 12 mg of betamethasone repeated at 24 hours.
Two days later, a caesarian section was performed because of signs of fetal distress by fetal heart rate monitoring. The child presented immediately difficulties in adapting to extrauterine life and was cared for in the pediatric intensive care unit (Figure 3). First aid revealed that the child was anemic at birth (hemoglobin at 11,8 g/dl) with a pulmonary arterial hypertension on cardiac ultrasound. A body scan (Figure 4) and a biopsy of a cutaneous tumor were performed and showed characteristics of a rhabdoid tumor (small round nuclei, granular chromatin, and eosinophilic cytoplasm). The immunohistochemical analysis revealed a loss of SMARCB1 protein expression and pathological examination of the placenta showed an invasion of both fetal and maternal compartments (Figure 5). Because of prematurity, circulatory failure, and severe renal dysfunction with anuria, chemotherapy was contraindicated, and the decision was made with the parents to withdraw care. The child died at day 5 of multivisceral failure. The mother underwent a whole-body MRI to identify potential metastasis, but none was found.
The INI1/SMARCB1 analysis conducted by Sanger sequencing of all exons and exon/intron boundaries and a Multiplex Ligation-dependent Probe Amplification (MLPA) to detect copy number alterations revealed a homozygous deletion of the 9 exons in tumor DNA. This alteration was not found in the child’s germ line nor in the parents. Therefore, the hypothesis of an inherited predisposition involving the SMARCB1 gene was excluded, and the hypothesis of a postzygotic (de novo) genetic alteration was retained.
Fetal rhabdoid tumors are rare, aggressive, and often diagnosed at metastatic stage. They have a poor prognosis with a high mortality rate before one year of life. The average age at diagnosis is 11 months. These tumors are reported most frequently in the central nervous system, kidneys, and soft tissue. They are sometimes discovered in utero following severe anemia secondary to tumor rupture or on the presence of many disseminated nodules . Only 6 other cases of prenatal diagnosis of fetal rhabdoid tumor are described in literature. Their localization, the ultrasound description, the gestational age at diagnosis, and the placental tumor invasion are reported in Table 1 [2–8]. These tumors affected both boys and girls. They were in all cases diagnosed during the third trimester and invaded the placenta in 3 cases. They were most often metastatic at time of diagnosis and the birth occurred shortly after the diagnosis in all the cases with a survival less than 15 days.
F = female; M = male; WG: weeks of gestation; Chr: chromosome; NS: not specified.
The pathological diagnosis of rhabdoid tumor is based on characteristic cells with a round vesicular nucleus, a prominent nucleolus, and round or oval eosinophilic inclusion bodies. These cells show a deletion in chromosome 22q11 or mutations of the SMARCB1 gene, a tumor suppressor gene, by immunohistochemical analysis. The majority of rhabdoid tumors arise from somatic loss of both copies of SMARCB1, which affects the formation of chromatin remodeling complexes. SMARCB1 mutations can arise de novo or be secondary to a germline mutation, which should prompt genetic counseling . In the 6 cases described in literature, 3 gave the genetic characteristics of the tumor but only one evoked an abnormality of chromosome 22q11.
Invasion of both fetal and maternal compartments of the placenta by tumor cells is extremely rare. In the literature, 36 cases of invasion of chorionic villi (fetal space) have been reported, but only 3 cases have been reported with invasion of the intervillous space with a risk of maternal dissemination of the tumor [10, 11] (Table 2). There have been no cases of maternal disease after complete examination, but this possibility should be explored in order to treat the mother as soon as possible, if necessary.
Azathioprine is a reported mutagen in vitro and in vivo in mice, but no case of human fetal malignancy has been reported in connection with maternal treatment .
Rhabdoid fetal tumors are aggressive with a difficult ultrasound diagnosis and a poor prognosis. The placenta should be analyzed for infiltration of the maternal side and tumor dissemination. Genetic counseling should be recommended for antenatal diagnosis of SMARCB1 mutation, and preimplantation screening may be discussed in cases of germline mutation.
Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.
- H. Isaacs Jr., “Fetal and neonatal rhabdoid tumor,” Journal of Pediatric Surgery, vol. 45, no. 3, pp. 619–626, 2010.
- F. V. White, L. P. Dehner, D. A. Belchis et al., “Congenital disseminated malignant rhabdoid tumor: a distinct clinicopathologic entity demonstrating abnormalities of chromosome 22q11,” The American Journal of Surgical Pathology, vol. 23, no. 3, pp. 249–256, 1999.
- M. Ohyama, R. Ijiri, Y. Tanaka et al., “Congenital primitive epithelial tumor of the liver showing focal rhabdoid features, placental involvement, and clinical features mimicking multifocal hemangioma or stage 4S neuroblastoma,” Human Pathology, vol. 31, no. 2, pp. 259–263, 2000.
- F. Staehelin, H. Bissig, I. Hösli et al., “Inv(11)(p13p15) and Myf-3(MyoD1) in a malignant extrarenal rhabdoid tumor of a premature newborn,” Pediatric Research, vol. 48, no. 4, pp. 463–467, 2000.
- I. Hösli, W. Holzgreve, E. Danzer, and S. Tercanli, “Two case reports of rare fetal tumors: An indication for surface rendering?” Ultrasound in Obstetrics & Gynecology, vol. 17, no. 6, pp. 522–526, 2001.
- J. Leader, S. J. Carlan, and J. Blum, “Congenital malignant extrarenal rhabdoid tumor: Prenatal ultrasound findings,” Obstetrics & Gynecology, vol. 99, no. 5, pp. 949–951, 2002.
- I. B. Fuchs, W. Henrich, K. D. Kalache, F. Lippek, and J. W. Dudenhausen, “Prenatal sonographic features of a rhabdoid tumor of the kidney,” Ultrasound in Obstetrics & Gynecology, vol. 23, no. 4, pp. 407–410, 2004.
- J.-Y. Kwon, I. P. Kook, S. L. Ki, I. Y. Woo, and Y.-H. Kim, “Prenatal detection of congenital malignant extrarenal rhabdoid tumor primarily involving the right upper extremity that ruptured in utero,” Prenatal Diagnosis, vol. 29, no. 8, pp. 819–821, 2009.
- F. Bourdeaut et al., “Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor,” Clinical Cancer Research, vol. 17, pp. 31–38, 2011.
- P. Reif, N. Hofer, V. Kolovetsiou-Kreiner, C. Benedicic, and M. Ratschek, “Metastasis of an undifferentiated fetal soft tissue sarcoma to the maternal compartment of the placenta: Maternal aspects, pathology findings and review of the literature on fetal malignancies with placenta metastases,” Histopathology, vol. 65, no. 6, pp. 933–942, 2014.
- M. De Tar and J. S. Biggerstaff, “Congenital renal rhabdoid tumor with placental metastases: Immunohistochemistry, cytogenetic, and ultrastructural findings,” Pediatric and Developmental Pathology, vol. 9, no. 2, pp. 161–167, 2006.
- A. Natekar, A. Pupco, P. Bozzo, and G. Koren, “Safety of azathioprine use during pregnancy,” Canadian Family Physician, vol. 57, no. 12, pp. 1401-1402, 2011.
Copyright © 2018 Yolaine Joueidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.